PFM Health Sciences’s Veeva Systems VEEV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.3M Buy
+39,679
New +$9.32M 1.13% 31
2026
Q1
– Sell
-32,489
Closed -$7.25M – 102
2025
Q4
$7.25M Sell
32,489
-9,014
-22% -$2.39M 0.72% 42
2025
Q3
$12.4M Buy
+41,503
New +$11.7M 0.95% 34
2025
Q1
– Sell
-55,383
Closed -$11.6M – 93
2024
Q4
$11.6M Buy
55,383
+36,124
+188% +$7.94M 0.72% 39
2024
Q3
$4.04M Buy
+19,259
New +$3.81M 0.23% 55
2024
Q2
– Sell
-118,905
Closed -$27.5M – 92
2024
Q1
$27.5M Hold
118,905
– – 1.3% 30
2023
Q4
$22.9M Hold
118,905
– – 1.37% 26
2023
Q3
$24.2M Buy
118,905
+81,484
+218% +$16.4M 1.14% 38
2023
Q2
$7.4M Buy
+37,421
New +$6.82M 0.29% 63
2022
Q4
– Sell
-202,387
Closed -$33.4M – 98
2022
Q3
$33.4M Hold
202,387
– – 1.21% 38
2022
Q2
$40.1M Buy
+202,387
New +$37.2M 1.53% 24

Other funds holding VEEV

PFM Health Sciences's VEEV Position: Q3 2026 in Review

PFM Health Sciences opened a new position in Veeva Systems (VEEV) in Q3 2026: 39,679 shares worth $11.3M. The stake represents 1.13% of the portfolio and ranks #31 among its holdings. This is a return to the name: PFM Health Sciences previously reported a position in VEEV as recently as Q4 2025.

PFM Health Sciences first reported a position in VEEV in Q2 2022 and has held it in 11 quarters since. The position peaked at $40.1M in Q2 2022. 1,216 funds tracked by Wall St. Rank hold VEEV as of Q3 2026.

  • PFM Health Sciences held 39,679 shares of Veeva Systems worth $11.3M as of Q3 2026.
  • Veeva Systems was a new PFM Health Sciences position in Q3 2026.
  • Veeva Systems made up 1.13% of PFM Health Sciences's portfolio in Q3 2026, its #31 holding.
  • PFM Health Sciences first reported a position in Veeva Systems in Q2 2022 and has held it in 11 quarters since.
  • PFM Health Sciences's Veeva Systems position peaked at $40.1M in Q2 2022.
  • 1,216 funds tracked by Wall St. Rank held Veeva Systems as of Q3 2026.

Based on PFM Health Sciences's 13F filing for Q3 2026, filed 16 Nov 2026.